Evidence map›Paper›PMID 34094229›Full record

ArticleChemical science2020

Heparin reversal by an oligoethylene glycol functionalized guanidinocalixarene.

Qiaoxian Huang, Hong Zhao, Mingju Shui, Dong-Sheng Guo, Ruibing Wang

Open access · diamondAbstract read
In one paragraph

Article in Chemical science, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. ConeBeilstein journal of organic chemistry · 2026
    Article
  3. HEMA-Lysine-Based Cryogels for Highly Selective Heparin Neutralization.International journal of molecular sciences · 2024
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Dynamic Combinatorial Optimization ofJournal of medicinal chemistry · 2022
    Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 4 countries.

Qiaoxian HuangState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau Macau SAR China rwang@um.edu.mo.
Hong ZhaoCollege of Chemistry, Key Laboratory of Functional Polymer Materials (Ministry of Education), State Key Laboratory of Elemento-Organic Chemistry, Nankai University Tianjin China dshguo@nankai.edu.cn.
Mingju ShuiState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau Macau SAR China rwang@um.edu.mo.
Dong-Sheng GuoCollege of Chemistry, Key Laboratory of Functional Polymer Materials (Ministry of Education), State Key Laboratory of Elemento-Organic Chemistry, Nankai University Tianjin China dshguo@nankai.edu.cn.ORCID https://orcid.org/0000-0002-0765-5427
Ruibing WangState Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau Macau SAR China rwang@um.edu.mo.ORCID https://orcid.org/0000-0001-9489-4241
University of Macau · MONankai University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unfractionated heparin (UFH), a naturally occurring anionic polysaccharide, is widely used as an anticoagulant agent in clinical practice. When overdosed or used in sensitive patients, UFH may cause various risks and a UFH neutralizer needs to be administered immediately to reverse heparinization. However, the most common UFH neutralizer, protamine sulfate, often causes various adverse effects, some of which are life-threatening. Herein, we designed a highly biocompatible, oligoethylene glycol functionalized guanidinocalixarene (GC4AOEG) as an antidote against UFH. GC4AOEG and UFH exhibited a strong binding affinity, ensuring specific recognition and neutralization of UFH by GC4AOEG

Identifiers

PMID34094229
PMCPMC8162181
OpenAlexW3082554195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.